



## **Amgen files infringement lawsuit against Tanvex**

July 25, 2019

Tanvex BioPharma, Inc. submitted Biologics License Application (BLA) last year for its first biosimilar product, TX01, a proposed biosimilar to the reference product Neupogen® (filgrastim) which is indicated for chemotherapy induced neutropenia. On July 23, 2019, Amgen sued Tanvex BioPharma, Inc. (TWSE: 6541) and two of its affiliates in the Southern District of California alleging infringement of U.S. Patent No. 9,856,287 (the '287 patent) under the BPCIA.

According to Amgen's complaint, prior to the litigation the parties engaged in the patent dance, during which Amgen included the '287 patent on its subsection (/)(3)(A) patent list and the parties agreed to initially litigate only the '287 patent. Tanvex BioPharma, Inc. intends to defend this suit vigorously.

Per Dr. Chao, founder and CEO of Tanvex BioPharma, Inc., we are committed to bringing high quality biosimilar drugs and meet our mission in driving the greater good through safe, effective and affordable biosimilars.

### **About Tanvex**

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.